Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GSK 115523: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intram

 


GSK 115523: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intram


Trial Focus

Blood Diseases (Except Leukemia)

Objective

         This is a clinical trial of investigational Herpes Zoster vaccine GSK1437173A which will be administered by injection.

IRB Protocol #

13-0082

Trial Status

OPEN

Principle Investigator

JONATHAN GUTMAN

Sponsor

GlaxoSmithKline

Contact

GREGORY HEMENWAY at -- or --

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period will last at most 4 years. A follow up period will only be necessary if you show signs of having shingles. // Eligibility includes but is not limited to 18 years or older and who have received a transplant with their own blood stem cells.Eligibility includes but is not limited to 18 years or older and who have received a transplant with their own blood stem cells.